FDA warns Mohawk Laboratories that its hand sanitizer contained unacceptable acetaldehyde and acetal impurities.
What happened
FDA laboratory testing of three lots of Mohawk's Alcohol Antiseptic, 80% Topical Solution, Hand Sanitizer, and impurity results the firm supplied for additional lots showed acetaldehyde and acetal at unacceptable levels. FDA said the levels were above the USP limit for alcohol and showed quality assurance was not following current good manufacturing practice (CGMP), the required quality rules for drug manufacturing. The firm recalled the product nationwide on December 9, 2022.
What FDA found
The hand sanitizer was contaminated with acetaldehyde and acetal at unacceptable levels, which FDA said showed the company's quality assurance was not working under CGMP.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company did not have a specification for acetaldehyde and acetal for alcohol, a significant component of the drug product.
21 CFR 211.160(b)The company did not test each finished batch for acetaldehyde and acetal as required.
21 CFR 211.165The company's described methods, facilities, or controls for making drugs did not conform to CGMP.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
Respond in writing within 15 working days describing what the company has done to correct violations and prevent recurrence; if corrective actions are not complete, give reasons and a completion schedule. If the company resumes drug manufacturing, it must notify FDA before resuming and should use a qualified CGMP consultant.
Who should pay attention
- distributors and retailers of Mohawk hand sanitizer
- other OTC hand sanitizer manufacturers
- drug quality teams that buy alcohol ingredients
This is a summary. Read the original letter on fda.gov.